Atara Biotherapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$121M
R&D
$37M
D&A
$2M
Operating Income
$36M
EBITDA
$38M
Interest Expense
$4M
Interest Income
$683K
Other Income/Expense
$-34K
Pretax Income
$33M
Tax Provision
$31K
Net Income
$33M
Operating Margin
29.7%
Net Margin
27.1%
Effective Tax Rate
0.1%
Deferred Tax Assets
$2M
Deferred Tax Liabilities
$2M
DTA Valuation Allowance
$355M
Tax Credit Carryforwards
$8M
NOL Carryforwards
$290M
ETR (Continuing Operations)
0.1%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.3%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$5M
Revenue YoY Variation
-6.3%
Income YoY Variation
143.0%